
Pietro GIUSTi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2084896/publications.pdf Version: 2024-02-01



DIETRO CILISTI

#	Article	IF	CITATIONS
1	The Effect of C-Phycocyanin on Microglia Activation Is Mediated by Toll-like Receptor 4. International Journal of Molecular Sciences, 2022, 23, 1440.	4.1	5
2	Carotenoid Extract Derived from Euglena gracilis Overcomes Lipopolysaccharide-Induced Neuroinflammation in Microglia: Role of NF-κB and Nrf2 Signaling Pathways. Molecular Neurobiology, 2021, 58, 3515-3528.	4.0	14
3	Co-Ultramicronized Palmitoylethanolamide/Luteolin-Induced Oligodendrocyte Precursor Cell Differentiation is Associated With Tyro3 Receptor Upregulation. Frontiers in Pharmacology, 2021, 12, 698133.	3.5	5
4	Pre- and Early Post-treatment With Arthrospira platensis (Spirulina) Extract Impedes Lipopolysaccharide-triggered Neuroinflammation in Microglia. Frontiers in Pharmacology, 2021, 12, 724993.	3.5	13
5	Pharmacogenomic Characterization in Bipolar Spectrum Disorders. Pharmaceutics, 2020, 12, 13.	4.5	12
6	Editorial: Neuroinflammation and Its Resolution: From Molecular Mechanisms to Therapeutic Perspectives. Frontiers in Pharmacology, 2020, 11, 480.	3.5	6
7	Ciprofloxacin and levofloxacin attenuate microglia inflammatory response via TLR4/NF-kB pathway. Journal of Neuroinflammation, 2019, 16, 148.	7.2	275
8	New oral anti-coagulants versus vitamin K antagonists in high thromboembolic risk patients. PLoS ONE, 2019, 14, e0222762.	2.5	14
9	A co-ultramicronized palmitoylethanolamide/luteolin composite mitigates clinical score and disease-relevant molecular markers in a mouse model of experimental autoimmune encephalomyelitis. Journal of Neuroinflammation, 2019, 16, 126.	7.2	23
10	Co-Ultramicronized Palmitoylethanolamide/Luteolin Facilitates the Development of Differentiating and Undifferentiated Rat Oligodendrocyte Progenitor Cells. Molecular Neurobiology, 2018, 55, 103-114.	4.0	18
11	Active Induction of Experimental Autoimmune Encephalomyelitis in C57BL/6 Mice. Methods in Molecular Biology, 2018, 1727, 353-360.	0.9	17
12	A Model of Systemic Inflammation to Study Neuroinflammation. Methods in Molecular Biology, 2018, 1727, 361-372.	0.9	6
13	Bisdemethoxycurcumin and Its Cyclized Pyrazole Analogue Differentially Disrupt Lipopolysaccharide Signalling in Human Monocyte-Derived Macrophages. Mediators of Inflammation, 2018, 2018, 1-13.	3.0	5
14	Curcumin Prevents Acute Neuroinflammation and Long-Term Memory Impairment Induced by Systemic Lipopolysaccharide in Mice. Frontiers in Pharmacology, 2018, 9, 183.	3.5	73
15	An Inflammation-Centric View of Neurological Disease: Beyond the Neuron. Frontiers in Cellular Neuroscience, 2018, 12, 72.	3.7	320
16	Serum amyloid A primes microglia for ATP-dependent interleukin- $\hat{1}^2$ release. Journal of Neuroinflammation, 2018, 15, 164.	7.2	48
17	Phenolic 1,3â€diketones attenuate lipopolysaccharideâ€induced inflammatory response by an alternative magnesiumâ€mediated mechanism. British Journal of Pharmacology, 2017, 174, 1090-1103.	5.4	28
18	Real-practice thromboprophylaxis in atrial fibrillation. Acta Pharmaceutica, 2017, 67, 227-236.	2.0	3

#	Article	IF	CITATIONS
19	Neuroinflammation, Mast Cells, and Glia: Dangerous Liaisons. Neuroscientist, 2017, 23, 478-498.	3.5	87
20	Expression and Differential Responsiveness of Central Nervous System Glial Cell Populations to the Acute Phase Protein Serum Amyloid A. Scientific Reports, 2017, 7, 12158.	3.3	27
21	Molecular network-selected pharmacogenomics in a case of bipolar spectrum disorder. Pharmacogenomics, 2017, 18, 1631-1642.	1.3	4
22	Synaptic Plasticity, Dementia and Alzheimer Disease. CNS and Neurological Disorders - Drug Targets, 2017, 16, 220-233.	1.4	128
23	Reference Values for a Panel of Cytokinergic and Regulatory Lymphocyte Subpopulations. Immune Network, 2016, 16, 344.	3.6	15
24	Systematic Review of Pharmacological Properties of the Oligodendrocyte Lineage. Frontiers in Cellular Neuroscience, 2016, 10, 27.	3.7	65
25	Co-ultramicronized Palmitoylethanolamide/Luteolin Promotes the Maturation of Oligodendrocyte Precursor Cells. Scientific Reports, 2015, 5, 16676.	3.3	30
26	Ligand engagement of Toll-like receptors regulates their expression in cortical microglia and astrocytes. Journal of Neuroinflammation, 2015, 12, 244.	7.2	73
27	N-Palmitoylethanolamine and Neuroinflammation: a Novel Therapeutic Strategy of Resolution. Molecular Neurobiology, 2015, 52, 1034-1042.	4.0	105
28	Germ line polymorphisms as predictive markers for pre-surgical radiochemotherapy in locally advanced rectal cancer: a 5-year literature update and critical review. European Journal of Clinical Pharmacology, 2015, 71, 529-539.	1.9	4
29	Reply to: "Palmitoylethanolamide: problems regarding micronization, ultra-micronization and additives―Inflammopharmacology DOI:10.1007/s10787-014-0202-3. Inflammopharmacology, 2015, 23, 127-130.	3.9	0
30	Neuroinflammation, Microglia and Mast Cells in the Pathophysiology of Neurocognitive Disorders: A Review. CNS and Neurological Disorders - Drug Targets, 2015, 13, 1654-1666.	1.4	130
31	Mast cells, glia and neuroinflammation: partners in crime?. Immunology, 2014, 141, 314-327.	4.4	200
32	Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology, 2014, 22, 79-94.	3.9	85
33	Toll-Like Receptors 2, -3 and -4 Prime Microglia but not Astrocytes Across Central Nervous System Regions for ATP-Dependent Interleukin-11² Release. Scientific Reports, 2014, 4, 6824.	3.3	96
34	Phosphatidylserine and Curcumin Act Synergistically to Down-Regulate Release of Interleukin-1β from Lipopolysaccharide-Stimulated Cortical Primary Microglial Cells. CNS and Neurological Disorders - Drug Targets, 2014, 13, 792-800.	1.4	15
35	Intracellular Ion Channel CLIC1: Involvement in Microglia-Mediated β-Amyloid Peptide(1-42) Neurotoxicity. Neurochemical Research, 2013, 38, 1801-1808.	3.3	16
36	Glia and Mast Cells as Targets for Palmitoylethanolamide, an Anti-inflammatory and Neuroprotective Lipid Mediator. Molecular Neurobiology, 2013, 48, 340-352.	4.0	110

#	Article	IF	CITATIONS
37	Effects of the neurotoxin MPTP and pargyline protection on extracellular energy metabolites and dopamine levels in the striatum of freely moving rats. Brain Research, 2013, 1538, 159-171.	2.2	9
38	Astrocyte-Microglia Cooperation in the Expression of a Pro-Inflammatory Phenotype. CNS and Neurological Disorders - Drug Targets, 2013, 12, 608-618.	1.4	58
39	A 6-Hydroxydopamine In Vivo Model of Parkinson's Disease. Methods in Molecular Biology, 2012, 846, 355-364.	0.9	21
40	Microglia and mast cells: two tracks on the road to neuroinflammation. FASEB Journal, 2012, 26, 3103-3117.	0.5	221
41	Simultaneous measurement of phosphatidylglycerol and disaturatedâ€phosphatidylcholine palmitate kinetics from alveolar surfactant. Study in infants with stable isotope tracer, coupled with isotope ratio mass spectrometry. Journal of Mass Spectrometry, 2011, 46, 986-992.	1.6	10
42	Consumption of opioid analgesics in Italy: Light at the end of the tunnel?. European Journal of Pain, 2011, 15, 220-221.	2.8	8
43	A mouse model of high trait anxiety shows reduced heart rate variability that can be reversed by anxiolytic drug treatment. International Journal of Neuropsychopharmacology, 2011, 14, 1341-1355.	2.1	33
44	Antidepressant Drug Prescribing Patterns to Outpatients of an Italian Local Health Authority During the Years 1998 to 2008. Journal of Clinical Psychopharmacology, 2010, 30, 212-215.	1.4	7
45	Anticonvulsant, anxiolytic, and non-sedating actions of imidazenil and other imidazo-benzodiazepine carboxamide derivatives. Pharmacology Biochemistry and Behavior, 2010, 95, 383-389.	2.9	15
46	The P2X ₇ purinergic receptor: from physiology to neurological disorders. FASEB Journal, 2010, 24, 337-345.	0.5	305
47	Receptors as a Transducer in the Co-Occurrence of Neurological/Psychiatric and Cardiovascular Disorders: A Hypothesis. Cardiovascular Psychiatry and Neurology, 2009, 2009, 1-5.	0.8	7
48	Fluoxetine-induced proliferation and differentiation of neural progenitor cells isolated from rat postnatal cerebellum. Biochemical Pharmacology, 2008, 76, 391-403.	4.4	37
49	Melatonin signaling in mouse cerebellar granule cells with variable native MT1 and MT2 melatonin receptors. Brain Research, 2008, 1227, 19-25.	2.2	24
50	Generation of a α-synuclein-based rat model of Parkinson's disease. Neurobiology of Disease, 2008, 30, 8-18.	4.4	34
51	Ventricular cerebrospinal fluid melatonin concentrations investigated with an endoscopic technique. Journal of Pineal Research, 2007, 42, 113-118.	7.4	36
52	Evaluation of the prescription and utilization patterns of statins in an Italian local health unit during the period 1994–2003. European Journal of Clinical Pharmacology, 2007, 63, 197-203.	1.9	41
53	Synthesis, antioxidant activity and structure-activity relationships for a new series of 2-(N-acylaminoethyl)indoles with melatonin-like cytoprotective activity. Journal of Pineal Research, 2006, 40, 259-269.	7.4	31
54	Retrospective analysis of opioid prescriptions in cancer patients in a northern Italian Region. British Journal of Clinical Pharmacology, 2006, 62, 130-133.	2.4	14

#	Article	IF	CITATIONS
55	MEK inhibition exacerbates ischemic calcium imbalance and neuronal cell death in rat cortical cultures. European Journal of Pharmacology, 2006, 553, 18-27.	3.5	14
56	A proteomic approach in the study of an animal model of Parkinson's disease. Clinica Chimica Acta, 2005, 357, 202-209.	1.1	84
57	Indole-based analogs of melatonin: in vitro antioxidant and cytoprotective activities. Journal of Pineal Research, 2004, 36, 95-102.	7.4	39
58	αâ€ S ynuclein and Parkinson's disease. FASEB Journal, 2004, 18, 617-626.	0.5	262
59	Opioid prescription for terminally ill outpatients in a district of northern Italy: a retrospective survey. Pharmacological Research, 2003, 48, 75-75.	7.1	11
60	Opioids in Italy: is marketing more powerful than the law?. Lancet, The, 2003, 362, 78.	13.7	29
61	Opioid prescription for terminally ill outpatients in a district of northern Italy: a retrospective survey. Pharmacological Research, 2003, 48, 75-82.	7.1	20
62	Photoisomerization of fluvoxamine generates an isomer that has reduced activity on the 5-hydroxytryptamine transporter and does not affect cell proliferation. European Journal of Pharmacology, 2002, 450, 223-229.	3.5	16
63	Kainic acid induces selective mitochondrial oxidative phosphorylation enzyme dysfunction in cerebellar granule neurons: protective effects of melatonin and GSH ethyl ester. FASEB Journal, 2001, 15, 1786-1788.	0.5	34
64	Benzodiazepine Receptor Affinities, Behavioral, and Anticonvulsant Activity of 2-Aryl-2,5-dihydropyridazino[4,3-b]indol- 3(3H)-ones in Mice. Pharmacology Biochemistry and Behavior, 2000, 65, 475-487.	2.9	12
65	Intracellular glutathione levels determine cerebellar granule neuron sensitivity to excitotoxic injury by kainic acid. Brain Research, 2000, 862, 83-89.	2.2	34
66	Effect of acute and chronic tramadol on [3H]-norepinephrine-uptake in rat cortical synaptosomes. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1999, 23, 485-496.	4.8	21
67	Abecarnil enhances recovery from diazepam tolerance. Neuropharmacology, 1999, 38, 1281-1288.	4.1	7
68	A new place conditioning paradigm to study tolerance to opiates in mice. NeuroReport, 1999, 10, 517-521.	1.2	3
69	Title is missing!. International Journal of Peptide Research and Therapeutics, 1998, 5, 71-73.	0.1	0
70	Synthesis, conformational and pharmacological studies on dermorphin N-terminal tetrapeptide analogues. International Journal of Peptide Research and Therapeutics, 1998, 5, 71-73.	0.1	0
71	Acetylcholinesterase Inhibitors:  Synthesis and Structureâ^'Activity Relationships of ï‰-[N-Methyl-N-(3-alkylcarbamoyloxyphenyl)- methyl]aminoalkoxyheteroaryl Derivatives. Journal of Medicinal Chemistry, 1998, 41, 3976-3986.	6.4	73
72	Melatonin prevents the delayed death of hippocampal neurons induced by enhanced excitatory neurotransmission and the nitridergic pathway. FASEB Journal, 1998, 12, 725-731.	0.5	78

#	Article	IF	CITATIONS
73	Melatonin maintains glutathione homeostasis in kainic acidâ€exposed rat brain tissues. FASEB Journal, 1997, 11, 1309-1315.	0.5	96
74	Effect of acute and chronic tramadol on [³ H]â€5â€HT uptake in rat cortical synaptosomes. British Journal of Pharmacology, 1997, 122, 302-306.	5.4	46
75	Lack of anticonvulsant tolerance and benzodiazepine receptor down regulation with imidazenil in rats. British Journal of Pharmacology, 1996, 117, 647-652.	5.4	17
76	Neuroprotection by melatonin from kainateâ€induced excitotoxicity in rats. FASEB Journal, 1996, 10, 891-896.	0.5	151
77	Abecarnil, a ?-carboline derivative, does not exhibit anticonvulsant tolerance or withdrawal effects in mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 1996, 354, 612-7.	3.0	8
78	In vitro and in vivo protection against kainate-induced excitotoxicity by melatonin. Journal of Pineal Research, 1996, 20, 226-231.	7.4	56
79	Characterization of [³ H]â€imidazenil binding to rat brain membranes. British Journal of Pharmacology, 1995, 114, 1159-1164.	5.4	4
80	Chronic administration of an anticonvulsant dose of imidazenil fails to induce tolerance of GABAA receptor function in mice. European Journal of Pharmacology, 1994, 254, 299-302.	3.5	23
81	Physiological and Pharmacological Bases for the Diverse Properties of Benzodiazepines and their Congeners. Pharmacological Research, 1993, 27, 201-216.	7.1	17
82	Neuropharmacological evidence for an interaction between the GABA uptake inhibitor Cl-966 and anxiolytic benzodiazepines. Drug Development Research, 1990, 21, 217-225.	2.9	14
83	Synthesis and Quantitative Structure-Activity Relationships of Analeptic Agents Related to Dimefline. Archiv Der Pharmazie, 1989, 322, 257-261.	4.1	2
84	Some New Prazosin Analogues. Archiv Der Pharmazie, 1989, 322, 359-361.	4.1	4
85	An experimental study on dependence liability of zipeprol. Pharmacological Research, 1989, 21, 223-229.	7.1	3
86	Cyclovinylogues of Guanethidine. Archiv Der Pharmazie, 1988, 321, 57-59.	4.1	4
87	Are calcitonins analgesic and/or hyperalgesic?. Peptides, 1985, 6, 277-282.	2.4	10
88	Antinociceptive effect of some carboxypeptidase a inhibitors in comparison with D-phenylalanine. European Journal of Pharmacology, 1985, 116, 287-292.	3.5	3
89	Gas-liquid chromatographic determination of dextromethorphan in serum and brain. Journal of Chromatography A, 1977, 140, 270-274.	3.7	9